TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma
Tatiana Erazo(Memorial Sloan Kettering Cancer Center), Michael G. Kharas(Memorial Sloan Kettering Cancer Center)
Cited by 28
Related Papers
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells
|Journal of Clinical Investigation|2008|150
Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia
|Nature Communications|2019|146
HyperTRIBE uncovers increased MUSASHI-2 RNA binding activity and differential regulation in leukemic stem cells
|Nature Communications|2020|72
Canonical and Kinase Activity-Independent Mechanisms for Extracellular Signal-Regulated Kinase 5 (ERK5) Nuclear Translocation Require Dissociation of Hsp90 from the ERK5-Cdc37 Complex
|Molecular and Cellular Biology|2013|57
Brain Specific Kinase-1 BRSK1/SAD-B associates with lipid rafts: modulation of kinase activity by lipid environment
|Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids|2011|25